CAMBRIDGE, England--(BUSINESS WIRE)--clock.bio, a healthspan biotech, today announced it has raised $5.3 million in seed funding led by LocalGlobe, with participation from BlueYard Capital, Onsight Ventures, and Dr. Jonathan Milner, the Founder of Abcam. The company has made significant progress in decoding the biology of human rejuvenation, identifying more than 100 genes that jointly constitute an 'Atlas of Rejuvenation Factors.'.

英国剑桥--（商业新闻短讯）--healthspan生物技术公司clock.bio今天宣布，它已经筹集了530万美元的种子资金，由LocalGlobe牵头，BlueYard Capital、Onsight Ventures和Abcam创始人乔纳森·米尔纳博士参与。该公司在解码人类复兴生物学方面取得了重大进展，确定了100多个共同构成“复兴因素图谱”的基因。

While all somatic cells irreversibly age, stem cells have the unique ability to turn back the clock. Working with human induced pluripotent stem cells (iPSCs), clock.bio has developed a proprietary aging model that can force stem cells to age, faithfully recreating the known cellular hallmarks of aging.

虽然所有体细胞都不可逆转地衰老，但干细胞具有独特的逆转时钟的能力。clock.bio与人类诱导多能干细胞（iPSC）合作，开发了一种专有的衰老模型，可以迫使干细胞衰老，忠实地重建已知的衰老细胞标志。

This intervention triggers a self-rejuvenation mechanism, whereby iPSCs repair these hallmarks and turn young and healthy..

这种干预引发了一种自我复兴机制，iPSC可以修复这些标志，使其变得年轻健康

Located at the Milner Therapeutics Institute at the University of Cambridge, clock.bio has set out to decode this rejuvenation mechanism, understand which genes regulate this process, and translate the resulting insights to clinical applications. Running a genome-wide CRISPR screen, with single-cell RNA-sequencing of over 3 million cells that generated 20 terabytes of data, clock.bio was able to decode the “rejuvenation mechanism” innate in human stem cells, identifying more than 100 genes that jointly constitute an 'Atlas of Rejuvenation Factors.'.

。clock.bio通过对300多万个产生20TB数据的细胞进行单细胞RNA测序，运行全基因组CRISPR筛选，能够解码人类干细胞固有的“再生机制”，鉴定出100多个共同构成“再生因子图谱”的基因。

The company will now focus on validating these hits in somatic cells, analyzing the pathways at work, and mapping them to specific disease indications. clock.bio’s hypothesis is that understanding these genes associated with rejuvenation will enable the reversal of several aging hallmarks by repurposing existing drugs for increased healthspan.

该公司现在将专注于验证体细胞中的这些命中，分析工作中的途径，并将其映射到特定的疾病适应症。生物钟（clock.bio）的假设是，了解这些与年轻化相关的基因，可以通过重新利用现有药物来增加健康跨度，从而逆转几种衰老标志。

In addition, genetic targets for repair of individual aging hallmarks will be highly relevant for developing novel treatments of age-related disease..

此外，修复个体衰老标志的遗传靶标将与开发与年龄相关疾病的新型治疗方法高度相关。

“Our vision is to extend human healthspan by several years, in line with growing longevity. Our approach decodes an existing part of human biology, which makes us confident the findings will be translatable,” said Markus Gstöttner, CEO, clock.bio. “Running CRISPR screens across the full human genome constitutes an unbiased, comprehensive methodology, which now gives us more than one shot on target.

clock.bio首席执行官Markus Gstöttner说：“我们的愿景是随着寿命的增长，将人类健康跨度延长几年。我们的方法解码了人类生物学的现有部分，这使我们相信这些发现将是可翻译的。”在整个人类基因组中运行CRISPR屏幕构成了一种公正，全面的方法，现在可以为我们提供不止一次的机会。

We are thrilled to have reached this first major milestone with the support of our investors.”.

我们很高兴在投资者的支持下实现了这一第一个重大里程碑。”

'We’re excited to support clock.bio, whose approach provides a unique, high-throughput and rapid way to investigate the biology of rejuvenation,” said Ferdi Sigona, LocalGlobe. “The company’s atlas holds the potential to open up several new routes to treating age-related diseases. We’re committed to advancing these discoveries into clinical applications that could turn out to be transformative.”.

LocalGlobe的费迪·西格纳（FerdiSigona）说：“我们很高兴能支持clock.bio，它的方法为研究复兴生物学提供了一种独特、高通量和快速的方法。”。“该公司的atlas有可能开辟几种治疗与年龄有关的疾病的新途径。我们致力于将这些发现推进临床应用，最终可能会带来变革。”

The seed funding enabled clock.bio to generate its Atlas of Rejuvenation Factors and will also enable next steps in validation and target prioritization. The company has expanded its team through several critical hires, including the onboarding of Markus Gstöttner (CEO) and Rodrigo Santos (CTO). Together with Mark Kotter (Chairman and co-founder), the team will now focus on developing its findings and identifying the right partners to initiate clinical trials..

种子基金使clock.bio能够生成其复兴因素图谱，也将为验证和目标优先排序的后续步骤提供支持。该公司通过几次关键招聘扩大了团队规模，其中包括马库斯·格斯特纳（Markus Gstöttner）（首席执行官）和罗德里戈·桑托斯（Rodrigo Santos）（首席技术官）的入职。与Mark Kotter（董事长兼联合创始人）一起，该团队现在将专注于开发其发现并确定启动临床试验的正确合作伙伴。

About clock.bio

关于clock.bio

clock.bio is founded on the vision to increase human healthspan by developing novel treatments that can prevent and treat age-related diseases by decoding the rejuvenation programs present in human cells. The company is structured as a partnership of scientists and operators bound together by a shared ethical outlook.

clock.bio建立在通过开发新的治疗方法来增加人类健康跨度的愿景之上，这种治疗方法可以通过解码人类细胞中存在的复兴程序来预防和治疗与年龄相关的疾病。

Our belief is that rejuvenation treatments need to be accessible to everyone, everywhere. For more information, visit www.clock.bio..

我们的信念是，任何地方的每个人都需要接受复兴疗法。有关更多信息，请访问www.clock.bio。